OptimizeRx Corporation

NASDAQ:OPRX

Medical - Healthcare Information Services

Healthcare
$7.31 -0.98%

-$0.05 today

Market cap
$138.21M
Beta
1.10
P/E (TTM)
13.8
EPS (TTM)
$0.36
52W Low $4.57High $22.25

Volume 0.18M

Average 0.47M

OPRX EPS (Diluted)

Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.

OptimizeRx CorporationNASDAQ: OPRX

EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026

EPS (Diluted) remains negative

Q1 FY2026 EPS (Diluted) was -$0.03, compared with -$0.12 a year earlier. Trailing-twelve-month EPS (Diluted) was $0.35.

Context

  • EPS (Diluted) increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EPS (Diluted) reaches the consensus estimate from 4 analysts of $0.84 (+209.6%) for the fiscal year ending Dec 2026, a step up from the +124.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$0.03-110.2% QoQ
Last fiscal yearDec 2025
$0.27+124.5% YoY
LTMMar 2026
$0.35+142.0% YoY
EPS (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+78.0%+37.9%-40.1 pp
1 year+124.5%+209.6%+85.1 pp
3-year CAGR—+56.3%—
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Diluted) history

USD · from the income statement

Latest · FY2025
0.27 USD
Year-over-year change
+124.5%
4-year CAGR
+88.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Diluted) vs competitors

How OPRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +142.0% is the 2nd highest of 10, against a peer median of -61.4%.
OPRX Competitors
EPS (Diluted) for OPRX and competitors
Company Period LTM YoY 3-year CAGR
SPOKSpok Holdings, Inc.LTM Mar 2026$0.6 USD-23.1%-11.7%
NRCNational Research CorporationLTM Mar 2026$0.4 USD-61.4%-25.7%
OPRXOptimizeRx CorporationLTM Mar 2026$0.35 USD+142.0%—
TBRGTruBridge, Inc.LTM Mar 2026$0.29 USD+247.5%-35.5%
RXSTRxSight, Inc.LTM Mar 2026-$1.13 USD-68.7%—
SOPHSOPHiA GENETICS S.A.LTM Mar 2026-$1.18 USD-18.0%—
DHDefinitive Healthcare Corp.LTM Mar 2026-$1.62 USD+63.1%—
SLPSimulations Plus, Inc.LTM Feb 2026-$3.13 USD-988.8%—
DRUGBright Minds Biosciences Inc.LTM Mar 2026-CA$3.24 CAD-336.0%—
NAKANakamoto Inc.LTM Mar 2026-$29.55 USD-3947.9%—
Peer median (excluding OPRX) —-61.4%-25.7%

Competitors are the stored peer set for OPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue61.29M62.45M71.52M92.13M109.43M
Cost of Revenue25.65M23.48M28.62M32.75M40.16M
Gross Profit35.64M38.97M42.9M59.38M69.27M
Gross Margin58.1%62.4%60.0%64.5%63.3%
Research & Development00000
Selling, General & Admin33.19M49.24M58.02M61.27M50.25M
Operating Expenses35.28M51.26M69.3M73.08M57.21M
Depreciation & Amortization1.97M2.02M2.4M4.33M4.33M
EBITDA2.34M(9.42M)(21.31M)(8.9M)16.57M
EBITDA Margin3.8%-15.1%-29.8%-9.7%15.1%
Operating Income361.1K(12.29M)(26.4M)(13.71M)12.06M
Operating Margin0.6%-19.7%-36.9%-14.9%11.0%
Interest Income16.98K852.3K2.19M329K353K
Interest Expense001.45M6.16M5.29M
Other Income / Expenses16.98K852.3K1.24M(5.68M)(5.11M)
Income Before Tax378.08K(11.44M)(25.16M)(19.39M)6.95M
Pre-Tax Margin0.6%-18.3%-35.2%-21.0%6.4%
Income Tax Expense00(7.6M)725K1.82M
Net Income378.08K(11.44M)(17.57M)(20.11M)5.13M
Net Margin0.6%-18.3%-24.6%-21.8%4.7%
EPS (Basic)0.02(0.64)(1.03)(1.10)0.28
EPS (Diluted)0.02(0.64)(1.03)(1.10)0.27
Weighted Avg Shares17.23M17.78M17.12M18.29M18.56M
Weighted Avg Shares (Diluted)17.69M17.78M17.12M18.29M19M

OptimizeRx Corporation

NASDAQ:OPRX

Intrinsic Alpha fair value

Locked

Current Price

$7.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.